Benign paroxysmal positional vertigo: is hypothyroidism a risk factor for recurrence?

IF 2.1 4区医学 Q2 OTORHINOLARYNGOLOGY Acta Otorhinolaryngologica Italica Pub Date : 2022-10-01 DOI:10.14639/0392-100X-N1775

Laura Tricarico, Tiziana Di Cesare, Jacopo Galli, Anna Rita Fetoni, Gaetano Paludetti, Pasqualina Maria Picciotti

{"title":"Benign paroxysmal positional vertigo: is hypothyroidism a risk factor for recurrence?","authors":"Laura Tricarico, Tiziana Di Cesare, Jacopo Galli, Anna Rita Fetoni, Gaetano Paludetti, Pasqualina Maria Picciotti","doi":"10.14639/0392-100X-N1775","DOIUrl":null,"url":null,"abstract":"Objective: To investigate the relationship between risk of Benign Paroxysmal Positional Vertigo (BPPV) recurrence and hypothyroidism treated with hormone replacement therapy (HRT).Methods: 797 patients with idiopathic BPPV were divided into two groups: 250 patients with recurrence of BPPV (R-BPPV) and 547 patients without recurrence (NR-BPPV). Regarding patients with thyroid disease on HRT, we collected serum test results of thyroid-stimulating hormone (TSH), free triiodothyronine f-T3, free thyroxine f-T4, thyroglobulin antibodies (TG-Ab) and thyroid peroxidase antibodies (TPO-Ab).Results: Hypothyroidism in long-term HRT was found in 61/250 (24.4%) patients of the R-BPPV group vs 79/547 (14.4%) of the NR-BPPV-group (p = 0.0006). Hashimoto thyroiditis (HT) was associated with recurrence (p < 0.0001). A significant correlation was found between recurrence and level of serum TPO-Ab (p = 0.0117) and TG-Ab (p = 0.0025), but not with mean serum TSH, f-T3 and f-T4.Conclusions: We assume that patients with hypothyroidism in HRT have an increased risk of BPPV recurrence, which is particularly strong for patients with HT and positive thyroid antibodies, suggesting an association between autoimmunity and recurrent vertigo.","PeriodicalId":6890,"journal":{"name":"Acta Otorhinolaryngologica Italica","volume":"42 5","pages":"465-470"},"PeriodicalIF":2.1000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Otorhinolaryngologica Italica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.14639/0392-100X-N1775","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}

引用次数: 3

Abstract

Objective: To investigate the relationship between risk of Benign Paroxysmal Positional Vertigo (BPPV) recurrence and hypothyroidism treated with hormone replacement therapy (HRT).

Methods: 797 patients with idiopathic BPPV were divided into two groups: 250 patients with recurrence of BPPV (R-BPPV) and 547 patients without recurrence (NR-BPPV). Regarding patients with thyroid disease on HRT, we collected serum test results of thyroid-stimulating hormone (TSH), free triiodothyronine f-T3, free thyroxine f-T4, thyroglobulin antibodies (TG-Ab) and thyroid peroxidase antibodies (TPO-Ab).

Results: Hypothyroidism in long-term HRT was found in 61/250 (24.4%) patients of the R-BPPV group vs 79/547 (14.4%) of the NR-BPPV-group (p = 0.0006). Hashimoto thyroiditis (HT) was associated with recurrence (p < 0.0001). A significant correlation was found between recurrence and level of serum TPO-Ab (p = 0.0117) and TG-Ab (p = 0.0025), but not with mean serum TSH, f-T3 and f-T4.

Conclusions: We assume that patients with hypothyroidism in HRT have an increased risk of BPPV recurrence, which is particularly strong for patients with HT and positive thyroid antibodies, suggesting an association between autoimmunity and recurrent vertigo.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

良性阵发性位置性眩晕:甲状腺功能减退是复发的危险因素吗?

目的:探讨激素替代疗法(HRT)治疗良性阵发性体位性眩晕(BPPV)复发风险与甲状腺功能减退的关系。方法:将797例特发性BPPV患者分为复发BPPV (R-BPPV) 250例和无复发BPPV (NR-BPPV) 547例两组。对接受HRT治疗的甲状腺疾病患者，收集血清促甲状腺激素(TSH)、游离三碘甲状腺原氨酸f-T3、游离甲状腺素f-T4、甲状腺球蛋白抗体(TG-Ab)和甲状腺过氧化物酶抗体(TPO-Ab)的检测结果。结果:R-BPPV组长期HRT患者中有61/250例(24.4%)出现甲状腺功能减退，而nr - bppv组为79/547例(14.4%)(p = 0.0006)。桥本甲状腺炎(HT)与复发相关(p < 0.0001)。复发率与血清TPO-Ab水平(p = 0.0117)、TG-Ab水平(p = 0.0025)有显著相关性，与平均血清TSH、f-T3、f-T4无显著相关性。结论:我们认为HRT中甲状腺功能减退的患者BPPV复发的风险增加，尤其是HT和甲状腺抗体阳性的患者，这表明自身免疫与复发性眩晕之间存在关联。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Acta Otorhinolaryngologica Italica OTORHINOLARYNGOLOGY-

CiteScore

3.40

自引率

10.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Acta Otorhinolaryngologica Italica first appeared as “Annali di Laringologia Otologia e Faringologia” and was founded in 1901 by Giulio Masini. It is the official publication of the Italian Hospital Otology Association (A.O.O.I.) and, since 1976, also of the Società Italiana di Otorinolaringoiatria e Chirurgia Cervico-Facciale (S.I.O.Ch.C.-F.). The journal publishes original articles (clinical trials, cohort studies, case-control studies, cross-sectional surveys, and diagnostic test assessments) of interest in the field of otorhinolaryngology as well as clinical techniques and technology (a short report of unique or original methods for surgical techniques, medical management or new devices or technology), editorials (including editorial guests – special contribution) and letters to the Editor-in-Chief. Articles concerning science investigations and well prepared systematic reviews (including meta-analyses) on themes related to basic science, clinical otorhinolaryngology and head and neck surgery have high priority.